Key result
Low molecular weight heparin (LMWH) provides an advantage over vitamin K antagonists during the first 3 to 6 months after acute DVT and/or PE in patients with cancer.
Why the study?
What is the optimal therapeutic approach for managing acute venous thromboembolism in patients with cancer?
What is the optimal therapeutic approach for managing acute venous thromboembolism in patients with cancer?
LMWH is preferred over VKAs for the initial 3-6 months of VTE treatment in cancer patients, though optimal long-term strategies and the role of DOACs require further investigation.
Answers are grounded in this paper and cite their sources.
Supports LMWH over VKAs initially in cancer VTE; leaves open long-term strategies and DOAC role.
INTRODUCTION: Cancer and venous thromboembolism (VTE) are closely related, with a high risk of VTE associated with cancer and a strong impact of VTE on cancer prognosis. The management and treatment of cancer-associated VTE are particularly challenging and, in many cases, are not guided by a high level of evidence. AREAS COVERED: In this review, we present the best therapeutic approach to acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and to some controversial issues, such as home treatment, optimal duration of anticoagulation, management of VTE recurrence during anticoagulant treatment, and of unsuspected PE. Then, the available evidence on other cancer-related VTE manifestations is presented, such as catheter-related thrombosis and splanchnic vein thrombosis. EXPERT OPINION: While solid evidence exists on the advantage of low molecular weight heparin (LMWH) over vitamin K antagonists (VKAs) during the first 3 to 6 months after acute DVT and/or PE, several issues have not been sufficiently investigated yet. These include the role of LMWH beyond the first 3 to 6 months, whether it is still more effective than VKA and if its intensity could be safely reduced, the strategies to identifying accurate predictors of VTE recurrence and the role of direct oral anticoagulants.
No takes yet. Share an insight, caveat, or question.
Donadini et al. (2015) conducted a review in Cancer and acute venous thromboembolism. Low molecular weight heparin (LMWH) vs. Vitamin K antagonists (VKAs) was evaluated. Low molecular weight heparin (LMWH) provides an advantage over vitamin K antagonists during the first 3 to 6 months after acute DVT and/or PE in patients with cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: